Madrigal Pharmaceuticals Announces Q4 and Full-Year 2025 Financial Results Release and Webcast on February 19, 2026
ByAinvest
Monday, Feb 2, 2026 8:07 am ET1min read
MDGL--
Madrigal Pharmaceuticals will release its Q4 and full-year 2025 financial results on Feb. 19, 2026. The company will host a live webcast at 8 a.m. Eastern Time to review the results. Madrigal's medication, Rezdiffra (resmetirom), is approved for treating MASH with moderate to advanced fibrosis. An ongoing Phase 3 trial evaluates Rezdiffra for treating compensated MASH cirrhosis.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet